Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on EquityReturn on Sales

Summit Therapeutics (SMMT) Net Margin (2016 - 2024)

Historic Net Margin for Summit Therapeutics (SMMT) over the last 6 years, with Q3 2022 value amounting to 7700.0%.

  • Summit Therapeutics' Net Margin changed N/A to 7700.0% in Q3 2022 from the same period last year, while for Sep 2025 it was 3.5231079858176e18%, marking a year-over-year decrease of 3.5231079858176013e22%. This contributed to the annual value of 11174.75% for FY2022, which is 62769100.0% down from last year.
  • As of Q3 2022, Summit Therapeutics' Net Margin stood at 7700.0%.
  • Over the past 5 years, Summit Therapeutics' Net Margin peaked at 1423.47% during Q1 2019, and registered a low of 7700.0% during Q3 2022.
  • In the last 4 years, Summit Therapeutics' Net Margin had a median value of 1437.41% in 2018 and averaged 2504.12%.
  • As far as peak fluctuations go, Summit Therapeutics' Net Margin surged by 2185300bps in 2018, and later crashed by -58529500bps in 2019.
  • Over the past 4 years, Summit Therapeutics' Net Margin (Quarter) stood at 1581.11% in 2018, then crashed by -333bps to 6841.94% in 2019, then soared by 59bps to 2775.1% in 2020, then crashed by -177bps to 7700.0% in 2022.
  • Its Net Margin was 7700.0% in Q3 2022, compared to 2775.1% in Q1 2020 and 6841.94% in Q4 2019.